RE-IMAGINE
MENTAL HEALTHCAREÂ
Transforming neuroscience-based innovation into accessible mental health therapy to help change lives.
GrayMatters Health is leading a transformation by empowering mental healthcare professionals with a neuroscience-based technology that augments standard-of-care therapies to improve patient outcomes and patient lives. This is all based on the world’s first PTSD treatment based on a digital biomarker of brain activity associated with mental health disorders.
​
Prism for PTSD is the first self-neuromodulation device to receive FDA clearance as a prescribed adjunct to psychotherapy and pharmacotherapy for post-traumatic stress disorder (PTSD). The procedure is a new concept – gamifying brain activity associated with PTSD, giving patients an active role in learning to control brain activity and improve their symptoms.
PRISM EMPOWERS
IT IS SCIENCE-BASEDâ€.‬
Prism’s amygdala-based biomarker technology
has been extensively researched.
IT FITS YOUR CLINIC
Installation and training in the morning and treat patients that same afternoon. Can be operated by a non-MD.
IT WORKSâ€.‬
In the clinical trial, 67% of patients overall showed clinically significant symptom improvement and 32% were in remission three months after treatment.
PTSD IS PERSONAL
By gamifying brain activity associated with PTSD, patients take an active role in improving their symptoms.
IT IS SAFEâ€.‬
Only mild side effects were reported which self-resolved post treatment.
PATIENTS LIKE ITâ€.‬
Prism does not expose patients to trauma and studies have shown
90% compliance.